102 related articles for article (PubMed ID: 31113922)
1. [Research progress in the role of FBXW7 in drug resistance against non-small cell lung cancer].
Peng Z; Chen Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Apr; 44(4):444-448. PubMed ID: 31113922
[TBL] [Abstract][Full Text] [Related]
2. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
[TBL] [Abstract][Full Text] [Related]
3. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
Yokobori T; Yokoyama Y; Mogi A; Endoh H; Altan B; Kosaka T; Yamaki E; Yajima T; Tomizawa K; Azuma Y; Onozato R; Miyazaki T; Tanaka S; Kuwano H
Mol Cancer Res; 2014 Jan; 12(1):32-7. PubMed ID: 24165483
[TBL] [Abstract][Full Text] [Related]
4. FBXW7 suppresses epithelial-mesenchymal transition and chemo-resistance of non-small-cell lung cancer cells by targeting snai1 for ubiquitin-dependent degradation.
Xiao G; Li Y; Wang M; Li X; Qin S; Sun X; Liang R; Zhang B; Du N; Xu C; Ren H; Liu D
Cell Prolif; 2018 Oct; 51(5):e12473. PubMed ID: 30094882
[TBL] [Abstract][Full Text] [Related]
5. E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination.
Zhu H; Wang X; Zhou X; Lu S; Gu G; Liu C
Lab Invest; 2022 Nov; 102(11):1203-1213. PubMed ID: 35840806
[TBL] [Abstract][Full Text] [Related]
6. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
Ye M; Zhang Y; Zhang X; Zhang J; Jing P; Cao L; Li N; Li X; Yao L; Zhang J; Zhang J
Cancer Res; 2017 Jul; 77(13):3527-3539. PubMed ID: 28522751
[TBL] [Abstract][Full Text] [Related]
7. MiR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7.
Xiang J; Hang JB; Che JM; Li HC
Int J Clin Exp Pathol; 2015; 8(8):9147-53. PubMed ID: 26464659
[TBL] [Abstract][Full Text] [Related]
8. FBXW7: a critical tumor suppressor of human cancers.
Yeh CH; Bellon M; Nicot C
Mol Cancer; 2018 Aug; 17(1):115. PubMed ID: 30086763
[TBL] [Abstract][Full Text] [Related]
9. miR-367 promotes tumor growth by inhibiting FBXW7 in NSCLC.
Xiao G; Gao X; Sun X; Yang C; Zhang B; Sun R; Huang G; Li X; Liu J; Du N; Liu D; Liang R; Ren H; Qin S
Oncol Rep; 2017 Aug; 38(2):1190-1198. PubMed ID: 28656290
[TBL] [Abstract][Full Text] [Related]
10. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
[TBL] [Abstract][Full Text] [Related]
12. FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
Morra F; Luise C; Merolla F; Poser I; Visconti R; Ilardi G; Paladino S; Inuzuka H; Guggino G; Monaco R; Colecchia D; Monaco G; Cerrato A; Chiariello M; Denning K; Claudio PP; Staibano S; Celetti A
Oncotarget; 2015 May; 6(14):12697-709. PubMed ID: 25885523
[TBL] [Abstract][Full Text] [Related]
13. [Effect of FBXW7 gene mutation on the prognosis of immunotherapy in patients with non-small cell lung cancer].
Liu XY; Cui YN; Li J; Zhang Z; Guo RH
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):914-921. PubMed ID: 35385962
[No Abstract] [Full Text] [Related]
14. FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein.
Zhang Y; Zhang X; Ye M; Jing P; Xiong J; Han Z; Kong J; Li M; Lai X; Chang N; Zhang J; Zhang J
Cancer Lett; 2018 Apr; 419():75-83. PubMed ID: 29355657
[TBL] [Abstract][Full Text] [Related]
15. mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.
Koo J; Yue P; Deng X; Khuri FR; Sun SY
Mol Cell Biol; 2015 Jul; 35(13):2344-55. PubMed ID: 25918246
[TBL] [Abstract][Full Text] [Related]
16. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.
Ding J; Zhao Z; Song J; Luo B; Huang L
Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):597-604. PubMed ID: 29701752
[TBL] [Abstract][Full Text] [Related]
17. Function and regulation of F-box/WD repeat-containing protein 7.
Zhang Z; Hu Q; Xu W; Liu W; Liu M; Sun Q; Ye Z; Fan G; Qin Y; Xu X; Yu X; Ji S
Oncol Lett; 2020 Aug; 20(2):1526-1534. PubMed ID: 32724394
[TBL] [Abstract][Full Text] [Related]
18. FBXW7 in breast cancer: mechanism of action and therapeutic potential.
Chen S; Leng P; Guo J; Zhou H
J Exp Clin Cancer Res; 2023 Sep; 42(1):226. PubMed ID: 37658431
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of FBXW7 loss of function in human cancers.
Fan J; Bellon M; Ju M; Zhao L; Wei M; Fu L; Nicot C
Mol Cancer; 2022 Mar; 21(1):87. PubMed ID: 35346215
[TBL] [Abstract][Full Text] [Related]
20. FBP1 inhibits NSCLC stemness by promoting ubiquitination of Notch1 intracellular domain and accelerating degradation.
He T; Wang Y; Lv W; Wang Y; Li X; Zhang Q; Shen HM; Hu J
Cell Mol Life Sci; 2024 Feb; 81(1):87. PubMed ID: 38349431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
